Press Releases Archive

2020-09-16 kl. 12:48

Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!

2020-08-25 kl. 07:30 (Regulatoriskt)

Interim Report Q2, 2020

2020-06-26 kl. 12:30 (Regulatoriskt)

SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue

2020-06-18 kl. 14:30

Wider range of prospective patients in the UK, Canada and the US for continued clinical study

2020-06-16 kl. 17:19

A future alternative to hormonal treatment for prostate cancer

2020-06-01 kl. 18:54 (Regulatoriskt)

Subscription period postponed for the rights issue. Other conditions remain unchanged

2020-06-01 kl. 13:12 (Regulatoriskt)

Patent application submitted to protect new technology

2020-06-01 kl. 12:45 (Regulatoriskt)

SpectraCure's MSEK 140 rights issue of units is fully guaranteed

2020-05-28 kl. 13:45 (Regulatoriskt)

SpectraCure AB Quarterly Report (1 Jan to 31 March) 2020

2020-04-07 kl. 09:00 (Regulatoriskt)

Patent application enters PCT phase, SpectraCure ensures development and work

2020-03-16 kl. 12:15 (Regulatoriskt)

New study underway in the US and approval from the Food and Drug Administration (FDA)

2020-03-12 kl. 10:35 (Regulatoriskt)

The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020

2020-03-06 kl. 10:30 (Regulatoriskt)

Agreement reached between SpectraCure and one more hospital - Memorial Sloan Kettering Cancer Center i n New York

2020-02-24 kl. 10:30 (Regulatoriskt)

Reinforcements in SpectraCure's organization

2020-01-17 kl. 13:50 (Regulatoriskt)

A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU.

2019-12-04 kl. 08:15 (Regulatoriskt)

Exercise rate of 98.8 percent for SpectraCure's warrants (TO3)

2019-11-26 kl. 14:56 (Regulatoriskt)

Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27

2019-11-13 kl. 13:20 (Regulatoriskt)

SpectraCure´s main owner subscribes in full for his share

2019-11-12 kl. 13:00 (Regulatoriskt)

SpectraCure AB Quarterly Report (1 July to 30 September) 2019

2019-10-28 kl. 10:10 (Regulatoriskt)

The FDA's initiative can provide faster market access for SpectraCure

2019-10-16 kl. 10:02 (Regulatoriskt)

SpectraCure at Stora Aktiedagen in Gothenburg

2019-10-07 kl. 09:26 (Regulatoriskt)

SpectraCure to the Premier Segment of First North Growth Market

2019-09-24 kl. 15:27 (Regulatoriskt)

Correction: Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial

2019-09-24 kl. 13:35 (Regulatoriskt)

Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial

2019-09-16 kl. 09:15 (Regulatoriskt)

SpectraCure presentations at investor meetings this fall

2019-08-22 kl. 09:40 (Regulatoriskt)

SpectraCure strengthens the organization with a PR Manager

2019-08-21 kl. 13:00 (Regulatoriskt)

SpectraCure AB Quarterly report (1 April to 30 June) 2019

2019-08-14 kl. 10:10 (Regulatoriskt)

SpectraCures new generation P18

2019-07-08 kl. 08:45 (Regulatoriskt)

Great attention for SpectraCure in Boston

2019-07-02 kl. 14:15 (Regulatoriskt)

SpectraCure reports positive results from the company's clinical phase 1-study

2019-06-10 kl. 12:55 (Regulatoriskt)

SpectraCure presents results from Phase 1 study

2019-05-23 kl. 11:42 (Regulatoriskt)

Preliminary results from SpectraCure's prostate treatments

2019-04-10 kl. 09:46 (Regulatoriskt)

New patient treatment, phase 2 initiated

2019-04-05 kl. 12:53 (Regulatoriskt)

SpectraCure files for a new patent

2019-03-29 kl. 14:49 (Regulatoriskt)

Status report for phase 2 study

2019-03-01 kl. 07:37 (Regulatoriskt)

Final preparation for Phase 2 - SpectraCure extends contract with hospital in London

2019-02-15 kl. 08:22 (Regulatoriskt)

More results from Phase 1 study

2019-01-28 kl. 13:02 (Regulatoriskt)

Results from clinical study for patient 9 and 10

2017-11-22 kl. 13:47 (Regulatoriskt)

Results and strategies of the clinical studies were discussed with the responsible physician

2017-11-13 kl. 14:35 (Regulatoriskt)

PSA-values from clinical prostate trial mentioned on SpectraCure presentation at ”Stora Aktiedagen” in Stockholm

2017-11-13 kl. 07:30 (Regulatoriskt)

SpectraCure presents the company and the progress on their current clinical trial

2017-11-08 kl. 14:49 (Regulatoriskt)

The CEO of SpectraCure increases his shareholding through MK Capital

2017-10-18 kl. 08:54 (Regulatoriskt)

Imaging material from clinical Phase 1 study

2017-10-03 kl. 13:07 (Regulatoriskt)

Concept study for next generation product completed

2017-09-28 kl. 11:29 (Regulatoriskt)

More preliminary results from the clinical Phase 1 study

2017-09-06 kl. 08:31 (Regulatoriskt)

Positive preliminary results from the clinical Phase 1 study are presented at a scientific conference

2017-08-25 kl. 07:46 (Regulatoriskt)

Full drug dose achieved in prostate trial

2017-07-05 kl. 07:45 (Regulatoriskt)

EU Grant awarded through Vinnova

2017-06-26 kl. 08:47 (Regulatoriskt)

An additional patient has been treated in Toronto, Canada

2017-06-01 kl. 09:36 (Regulatoriskt)

Patent for dose control approved in Canada

2017-05-23 kl. 14:15 (Regulatoriskt)

Communiqué from the Annual General Meeting 2017

2017-05-18 kl. 10:58 (Regulatoriskt)

SpectraCure initiates a joint project with German company MedCom GmbH

2017-04-24 kl. 08:58 (Regulatoriskt)

Patient treatments started in clinical Phase 1 study

2017-04-21 kl. 07:17 (Regulatoriskt)

Notice of annual general Meeting of SpectraCure AB (publ)

2017-01-24 kl. 12:30 (Regulatoriskt)

The first day of trading with warrants of series TO2 is estimated at 27 January 2017

2017-01-18 kl. 16:03 (Regulatoriskt)

SpectraCure decides on Set-off Issue